904 results on '"Bitton, Alain"'
Search Results
2. After Surgically Induced Remission, Ileal and Colonic Mucosa-Associated Microbiota Predicts Crohn’s Disease Recurrence
3. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study
4. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
5. Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives
6. Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis
7. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
8. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study
9. Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease
10. Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease: A Canadian Nationwide Analysis.
11. Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study
12. Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study
13. Variation in the Care of Children with Inflammatory Bowel Disease Within and Across Canadian Provinces: A Multi-Province Population-Based Cohort Study
14. Hospitalization with Clostridioides difficile in pediatric inflammatory bowel disease: a population-based study
15. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy
16. Anti-microbial antibody response is associated with future onset of Crohn’s disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk
17. Laboratory Findings
18. Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn’s Disease
19. Efficacy and Safety of Upadacitinib During Induction in Crohn’s disease: Real-World Experience
20. Clinical Predictors of Early and Late Endoscopic Recurrence Following Ileocolonic Resection in Crohn’s Disease
21. Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease
22. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
23. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review
24. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data
25. Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic
26. Clinical Predictors of Early and Late Endoscopic Recurrence Following Ileocolonic Resection in Crohn's Disease.
27. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
28. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD
29. The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease
30. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—Children and Adolescents with IBD
31. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations—IBD in Seniors
32. The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care
33. The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD
34. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs
35. Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives
36. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD
37. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs
38. The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease
39. Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery
40. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of Population-Based Studies From Western Countries
41. Patients’ perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease
42. Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies
43. No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015
44. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival
45. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
46. Exploring the Use of a Participative Design in the Early Development of a Predictive Test : The Importance of Physician Involvement
47. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary
48. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease
49. Erratum: A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping?
50. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn’s Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.